{"filing":{"accession_number":"0001193125-26-252474","cik":"0001438533","ticker":"TVTX","company_name":"Travere Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-02","report_date":null,"primary_document":"d107618d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1438533/000119312526252474/d107618d8k.htm"},"events":[{"id":7432,"run_id":6531,"accession_number":"0001193125-26-252474","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"summary":"Travere entered into a material license and collaboration agreement with Everest Medicines on June 1, 2026, acquiring exclusive rights to develop and commercialize civorebrutinib (EVER001) in a broad territory outside China and certain Asian countries. The deal involves a $112.5 million upfront payment plus up to $1.03 billion in milestone payments, making it a material acquisition of intellectual property and development rights that would significantly affect investor assessment of the company's pipeline and financial obligations.","company_name":"Travere Therapeutics, Inc.","ticker":"TVTX","filing_date":"2026-06-02","form":"8-K","submitted_at":null,"items":[{"id":3532,"accession_number":"0001193125-26-252474","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Travere entered into a material license and collaboration agreement with Everest Medicines on June 1, 2026, acquiring exclusive rights to develop and commercialize civorebrutinib (EVER001) in a broad territory outside China and certain Asian countries. The deal involves a $112.5 million upfront payment plus up to $1.03 billion in milestone payments, making it a material acquisition of intellectual property and development rights that would significantly affect investor assessment of the company's pipeline and financial obligations.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-03T02:14:20.338069+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":3532,"accession_number":"0001193125-26-252474","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Travere entered into a material license and collaboration agreement with Everest Medicines on June 1, 2026, acquiring exclusive rights to develop and commercialize civorebrutinib (EVER001) in a broad territory outside China and certain Asian countries. The deal involves a $112.5 million upfront payment plus up to $1.03 billion in milestone payments, making it a material acquisition of intellectual property and development rights that would significantly affect investor assessment of the company's pipeline and financial obligations.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-03T02:14:20.338069+00:00","company_name":"Travere Therapeutics, Inc.","ticker":"TVTX","filing_date":"2026-06-02"}]}